ViiV Healthcare reported interim results for two investigational HIV medications—both look promising.
In 48-week results from the phase 3 BRIGHTE study of investigational fostemsavir in heavily treatment-experienced (HTE) patients with HIV, fostemsavir with optimized background therapy (OBT) maintained virologic suppression from weeks 24 to 48.
In 48-week results from the phase 3 FLAIR (First Long-Acting Injectable Regimen) trial of a long-acting, injectable two-drug regimen for the